{"log_id": 4401006033532036115, "direction": 0, "words_result_num": 54, "words_result": [{"probability": {"variance": 0.000526, "average": 0.993495, "min": 0.85798}, "location": {"width": 775, "top": 83, "height": 29, "left": 304}, "words": "解到2级,才能以较低的调整剂量重新开始治疗(第2次发生:200mg/m2体表面积;第"}, {"probability": {"variance": 0.032473, "average": 0.870749, "min": 0.615913}, "location": {"width": 116, "top": 100, "height": 55, "left": 169}, "words": "药有限"}, {"probability": {"variance": 0.000773, "average": 0.988156, "min": 0.896139}, "location": {"width": 277, "top": 112, "height": 28, "left": 302}, "words": "3次发生:150mg/m2体表面积)"}, {"probability": {"variance": 0.009141, "average": 0.981123, "min": 0.408114}, "location": {"width": 800, "top": 140, "height": 34, "left": 275}, "words": "如严重的皮肤反应为第4次发生,或停药后皮肤反应无法缓解至2级,则须永久停"}, {"probability": {"variance": 5.6e-05, "average": 0.994385, "min": 0.97616}, "location": {"width": 186, "top": 174, "height": 29, "left": 302}, "words": "北应用本品进行治疗"}, {"probability": {"variance": 0.000763, "average": 0.979373, "min": 0.925043}, "location": {"width": 108, "top": 207, "height": 23, "left": 342}, "words": "电解质紊乱:"}, {"probability": {"variance": 0.000361, "average": 0.99278, "min": 0.906138}, "location": {"width": 729, "top": 234, "height": 27, "left": 341}, "words": "血清镁水平的进行性降低较常发生,并可能由此导致严重的低镁血症。停止西妥昔单抗"}, {"probability": {"variance": 0.007146, "average": 0.983186, "min": 0.535939}, "location": {"width": 564, "top": 262, "height": 27, "left": 301}, "words": "治疗后低镁血症是可逆的。此外,低镁血症也可能是腹泻的继发症"}, {"probability": {"variance": 0.000681, "average": 0.991032, "min": 0.878496}, "location": {"width": 730, "top": 295, "height": 25, "left": 340}, "words": "在西妥昔单抗的治疗过程中,建议在开始治疗前以及治疗过程中周期性的监测血清电解"}, {"probability": {"variance": 0.000732, "average": 0.989826, "min": 0.880619}, "location": {"width": 446, "top": 323, "height": 26, "left": 301}, "words": "质水平。也建议在适当情况下进行电解质的补充治疗"}, {"probability": {"variance": 1e-06, "average": 0.999314, "min": 0.997948}, "location": {"width": 87, "top": 352, "height": 25, "left": 339}, "words": "特殊人群"}, {"probability": {"variance": 0.00025, "average": 0.995149, "min": 0.905736}, "location": {"width": 727, "top": 378, "height": 32, "left": 338}, "words": "到目前为止,仅对肝肾功能正常的患者(血清肌酐≤正常值上限的1.5倍,转氨酶"}, {"probability": {"variance": 8e-05, "average": 0.995828, "min": 0.955477}, "location": {"width": 687, "top": 408, "height": 30, "left": 300}, "words": "≤正常值上限的5倍,胆红素≤正常值上限的1.5倍)进行过本品的相关研究"}, {"probability": {"variance": 5e-06, "average": 0.997766, "min": 0.990268}, "location": {"width": 553, "top": 440, "height": 27, "left": 338}, "words": "尚无本品对以下一项或多项实验室指标异常的患者的用药经验:"}, {"probability": {"variance": 0.007443, "average": 0.967222, "min": 0.709064}, "location": {"width": 141, "top": 470, "height": 25, "left": 374}, "words": "血红蛋白<9g/dl"}, {"probability": {"variance": 0.000212, "average": 0.989665, "min": 0.95399}, "location": {"width": 177, "top": 499, "height": 24, "left": 375}, "words": "白细胞计数<3000/m"}, {"probability": {"variance": 0.004862, "average": 0.972, "min": 0.694303}, "location": {"width": 292, "top": 527, "height": 26, "left": 373}, "words": "绝对嗜中性粒细胞计数<1500/m3"}, {"probability": {"variance": 0.011565, "average": 0.93283, "min": 0.595042}, "location": {"width": 194, "top": 554, "height": 26, "left": 373}, "words": "血小板计数<0000/m"}, {"probability": {"variance": 0.001039, "average": 0.990993, "min": 0.840298}, "location": {"width": 465, "top": 582, "height": 27, "left": 334}, "words": "尚无儿童患者使用西妥昔单抗的安全性和有效性数据"}, {"probability": {"variance": 0.003124, "average": 0.971932, "min": 0.738337}, "location": {"width": 580, "top": 608, "height": 44, "left": 333}, "words": "西妥昔单抗与放疗联合应用治疗结直肠癌的经验有限药"}, {"probability": {"variance": 4.6e-05, "average": 0.997174, "min": 0.975385}, "location": {"width": 233, "top": 653, "height": 26, "left": 300}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.000101, "average": 0.995858, "min": 0.94017}, "location": {"width": 722, "top": 682, "height": 27, "left": 335}, "words": "GFR参与胎儿的发育,在动物研究中获得的有限证据显示本品能够穿过胎盘,同时"}, {"probability": {"variance": 0.000459, "average": 0.992037, "min": 0.8756}, "location": {"width": 768, "top": 707, "height": 33, "left": 290}, "words": "其它的IgG抗体也可以通过胎盘屏障,因此虽然在动物实验中未发现西妥昔单抗具有致"}, {"probability": {"variance": 0.000986, "average": 0.988651, "min": 0.809083}, "location": {"width": 765, "top": 736, "height": 33, "left": 291}, "words": "畸作用,但已观察到随着剂量的增加,流产的发生率会也随之增加参见“药理毒理”)。尚"}, {"probability": {"variance": 1e-05, "average": 0.998247, "min": 0.985958}, "location": {"width": 407, "top": 766, "height": 26, "left": 290}, "words": "未获得孕妇或哺乳期妇女应用本品的足够数据"}, {"probability": {"variance": 1e-05, "average": 0.998434, "min": 0.98384}, "location": {"width": 722, "top": 796, "height": 29, "left": 331}, "words": "强烈建议对于孕妇或者任何未采取充分避孕措施的妇女仅在其可能获得的受益大"}, {"probability": {"variance": 6.6e-05, "average": 0.995975, "min": 0.966075}, "location": {"width": 364, "top": 825, "height": 25, "left": 291}, "words": "于对胎儿的潜在风险时再接受本品的治疗"}, {"probability": {"variance": 0.005543, "average": 0.982923, "min": 0.548227}, "location": {"width": 722, "top": 854, "height": 28, "left": 331}, "words": "由于尚不清楚西妥昔单抗是否会分泌到乳汁中,建议哺乳期妇女在使用本品治疗期"}, {"probability": {"variance": 1e-06, "average": 0.998961, "min": 0.996924}, "location": {"width": 365, "top": 882, "height": 26, "left": 289}, "words": "间和最后一次用药后的2个月内不要哺乳"}, {"probability": {"variance": 1.2e-05, "average": 0.997893, "min": 0.989643}, "location": {"width": 172, "top": 919, "height": 25, "left": 293}, "words": "【驾车与操作机器】"}, {"probability": {"variance": 4.3e-05, "average": 0.99717, "min": 0.962793}, "location": {"width": 721, "top": 947, "height": 29, "left": 328}, "words": "尚未进行本品对驾车和操作机器影响的研究。如果患者发生与治疗相关的症状而影"}, {"probability": {"variance": 5e-06, "average": 0.998804, "min": 0.991673}, "location": {"width": 579, "top": 976, "height": 26, "left": 289}, "words": "响其注意力和反应能力时,建议在症状消退前不要驾车或操作机器"}, {"probability": {"variance": 2e-06, "average": 0.998556, "min": 0.996547}, "location": {"width": 112, "top": 1013, "height": 25, "left": 292}, "words": "【儿童用药】"}, {"probability": {"variance": 0.00732, "average": 0.979741, "min": 0.57925}, "location": {"width": 461, "top": 1043, "height": 27, "left": 325}, "words": "尚无儿童患者使用西妥昔单抗的安全性和有效性数据"}, {"probability": {"variance": 1e-06, "average": 0.998657, "min": 0.996616}, "location": {"width": 112, "top": 1080, "height": 25, "left": 290}, "words": "【老年用药】"}, {"probability": {"variance": 0.003338, "average": 0.986356, "min": 0.70354}, "location": {"width": 487, "top": 1107, "height": 26, "left": 325}, "words": "老年患者无需调整剂量。75岁以上患者的用药经验有限"}, {"probability": {"variance": 3e-06, "average": 0.998391, "min": 0.994144}, "location": {"width": 154, "top": 1144, "height": 25, "left": 288}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.0019, "average": 0.989443, "min": 0.735559}, "location": {"width": 720, "top": 1170, "height": 34, "left": 323}, "words": "伊立替康不会影响西妥昔单抗的安全性,反之亦然。一项正式的药物相互作用研究"}, {"probability": {"variance": 0.003888, "average": 0.983461, "min": 0.597679}, "location": {"width": 762, "top": 1199, "height": 35, "left": 282}, "words": "显示单剂量(350mg/m2体表面积)伊立替康不会影响本品的药代动力学特性。同样,本"}, {"probability": {"variance": 4e-06, "average": 0.998833, "min": 0.99235}, "location": {"width": 362, "top": 1231, "height": 23, "left": 281}, "words": "品也不会影响伊立替康的药代动力学特性"}, {"probability": {"variance": 4e-05, "average": 0.99738, "min": 0.971038}, "location": {"width": 402, "top": 1259, "height": 27, "left": 323}, "words": "尚未进行本品与其它药物相互作用的人体研究"}, {"probability": {"variance": 0, "average": 0.99944, "min": 0.998989}, "location": {"width": 112, "top": 1298, "height": 24, "left": 286}, "words": "【药物过量】"}, {"probability": {"variance": 0.000682, "average": 0.987899, "min": 0.851295}, "location": {"width": 720, "top": 1326, "height": 33, "left": 318}, "words": "目前对于单次剂量超过400mg/m2体表面积,或者每周给药剂量超过250mg/m2体表面积"}, {"probability": {"variance": 0.000605, "average": 0.991688, "min": 0.851832}, "location": {"width": 758, "top": 1354, "height": 32, "left": 283}, "words": "的经验有限。在临床研究中,每2周给药最高剂量700mg/m2体表面积条件下的安全性情况"}, {"probability": {"variance": 5e-06, "average": 0.998281, "min": 0.99314}, "location": {"width": 228, "top": 1383, "height": 25, "left": 284}, "words": "与“不良反应”中所述一致"}, {"probability": {"variance": 1e-06, "average": 0.999218, "min": 0.997335}, "location": {"width": 112, "top": 1420, "height": 24, "left": 286}, "words": "【药理毒理】"}, {"probability": {"variance": 0, "average": 0.999892, "min": 0.999826}, "location": {"width": 45, "top": 1450, "height": 24, "left": 319}, "words": "药理"}, {"probability": {"variance": 0.016331, "average": 0.960725, "min": 0.40251}, "location": {"width": 718, "top": 1477, "height": 33, "left": 319}, "words": "作用机制:西昔单抗属于嵌合型IgG1单克隆抗体,分子靶点为表皮生长因子受体"}, {"probability": {"variance": 0.006924, "average": 0.983423, "min": 0.451769}, "location": {"width": 747, "top": 1508, "height": 31, "left": 288}, "words": "(EGFR).EGFR信号途径参与控制细胞的存活、增殖、血管生成、细胞迁移、细胞侵袭"}, {"probability": {"variance": 0.000963, "average": 0.985177, "min": 0.855828}, "location": {"width": 758, "top": 1535, "height": 34, "left": 277}, "words": "及转移等。西妥昔单抗与EGFR结合的亲和力约为其内源性配体的5到10倍。西妥昔单抗"}, {"probability": {"variance": 4.4e-05, "average": 0.996415, "min": 0.965683}, "location": {"width": 757, "top": 1564, "height": 33, "left": 275}, "words": "阻断EGFR与其内源性配体的结合,从而抑制受体功能,进一步诱导EGFR的细胞内化从"}, {"probability": {"variance": 0.008901, "average": 0.978643, "min": 0.432298}, "location": {"width": 759, "top": 1593, "height": 35, "left": 275}, "words": "而导致受体数量的下调。西妥单抗还可以靶向诱导细胞毒免疫效应细胞作用于表达"}, {"probability": {"variance": 0.000462, "average": 0.991797, "min": 0.879773}, "location": {"width": 535, "top": 1626, "height": 25, "left": 278}, "words": "EGFR的肿瘤细胞(抗体依赖的细胞介导的细胞毒作用,ADCC)"}, {"probability": {"variance": 0.000794, "average": 0.988297, "min": 0.882872}, "location": {"width": 343, "top": 1655, "height": 26, "left": 314}, "words": "西妥昔单抗不与HER家族的其他受体结合"}], "language": 3}